No Data
No Data
GENOR-B: 2024 ANNUAL REPORT
Genor Biopharma Extends CEO's Contract For Two More Years
New stock news | Open up a new capital track for Hong Kong stocks 18A! Yiteng Pharmaceutical will conduct a stock swap reverse acquisition of GENOR-B (06998).
According to a disclosure by the Hong Kong Stock Exchange on April 15, GENOR-B (06998) has submitted a listing application to the Stock Exchange. Yiton Pharma has conducted a reverse acquisition of GENOR-B through a share swap, and after the merger, the company will be renamed "Yiton GENOR Pharmaceutical Group Limited."
GENOR-B (06998) announced its 2024 annual results, with a net loss of 52.974 million yuan, a year-on-year reduction of 92.2%.
GENOR-B (06998) released its 2024 annual performance, with a revenue of 0.206 billion yuan (Renminbi, the same below), ...
Express News | Genor Biopharma Holdings FY Revenue RMB 206.2 Million
GENOR-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024